2. Cytoskeleton
  3. Lysyl Oxidase
  4. LNO 9

LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension.

For research use only. We do not sell to patients.

LNO 9

LNO 9 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

LNO 9 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension[1].

In Vitro

LNO 9 (2 h) exhibits selective inhibition of human LOXL2 over human LOX, LOXL3, SSAO, DAO, MAO-A, and MAO-B, with an LOXL2 IC50 of 0.17 μM[1].
LNO 9 (20-40 μM; 24 h) significantly inhibits hypoxia-induced proliferation of HPASMCs, with efficacy superior to lenumlostat[1].
LNO 9 (20-40 μM; 24 h) significantly inhibits hypoxia-induced migration of HPASMCs, with efficacy superior to lenumlostat[1].
LNO 9 (20-40 μM) modulates sGC, YAP/TAZ, and fibrotic signaling pathways in hypoxia-induced HPASMCs, increasing p-VASP and p-YAP/p-TAZ while reducing PKG1, nuclear YAP/TAZ/TEAD4, α-SMA, collagen I, fibronectin 1, and p-Smad3[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LNO 9 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Hypoxia-induced human pulmonary arterial smooth muscle cells (HPASMCs)
Concentration: 20-40 μM
Incubation Time: 24 h
Result: Significantly suppressed hypoxia-induced HPASMC proliferation, with efficacy superior to lenumlostat at equivalent concentrations.

Cell Migration Assay [1]

Cell Line: Hypoxia-induced human pulmonary arterial smooth muscle cells (HPASMCs)
Concentration: 20-40 μM
Incubation Time: 24 h
Result: Significantly suppressed hypoxia-induced HPASMC migration, with greater efficacy than lenumlostat at equivalent concentrations.
In Vivo

LNO 9 (15-30 mg/kg; p.o.; once daily; for 14 consecutive days) can significantly reduce RVSP in hypoxia-induced pulmonary arterial hypertension rats through dual inhibition of LOXL2 and stimulation of sGC, while ameliorating right ventricular hypertrophy and inhibiting pulmonary vascular remodeling[1].
LNO 9 (15-30 mg/kg; p.o.; daily; 14 days) significantly reduces RVSP, ameliorates right ventricular hypertrophy, inhibits pulmonary vascular remodeling, and increases survival rate to 60% in monocrotaline (HY-N0750)-induced pulmonary hypertension rats via dual inhibition of LOXL2 and stimulation of sGC[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley rat with pulmonary arterial hypertension (male, 160-180 g, hypoxia-induced modeling)[1]
Dosage: 15 mg/kg; 30 mg/kg
Administration: p.o.; daily; 14 days
Result: Reduced right ventricular systolic pressure (RVSP) to 37.8 mmHg (vs. hypoxia model 50.8 mmHg) at 15 mg/kg, and to 29.9 mmHg (vs. hypoxia model 50.8 mmHg) at 30 mg/kg, with greater reduction than lenumlostat 30 mg/kg (43.3 mmHg).
Ameliorated right ventricular hypertrophy via decreased RV/(LV + S) ratio and RV/tibia length ratio, without reducing rat body weight.
Reduced total, soluble, and insoluble collagen content in pulmonary arteries, decreased collagen cross-linking (insoluble/soluble collagen ratio), and reduced pulmonary arterial medial wall thickness (PAMT%).
Increased pulmonary artery p-VASP protein levels and decreased PKG1, α-SMA, and collagen I protein levels compared to the hypoxia group.
Molecular Weight

544.45

Formula

C23H24F4N4O7
SMILES

NCC1=CC(C(F)(F)F)=NC(OC2=CC(C(N3C[C@H]([C@@H](C3)F)OC(CCCCO[N+]([O-])=O)=O)=O)=CC=C2)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LNO 9 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LNO 9LNO9LNO-9Lysyl Oxidasenitric oxidecollagen oxidationHPASMCspulmonary arterial hypertensionright ventricular hypertrophy293T cellssGCLTQ cofactorLOXL2pulmonary arterial smooth muscle cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LNO 9
Cat. No.:
HY-183644
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.